Is treatment with 6-mercaptopurine for colitis associated with the development of colorectal cancer?

Inflammatory Bowel Diseases

Volumn 19, Issue 4, 2013, Pages 785-788

  Satchi, Mylan ^a   Korelitz, Burton I ^a   Panagopoulos, Georgia ^a   Bratcher, Jason ^a   Yu, Christine ^a   Atallah Vinograd, Jean ^a   Schneider, Judy ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

6 MP treated colitis; Chemoprevention; Colon cancer

Indexed keywords

MERCAPTOPURINE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COLITIS; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; ULCERATIVE COLITIS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COLORECTAL TUMOR; FOLLOW UP; MIDDLE AGED; PROGNOSIS; PROPENSITY SCORE;

6-MERCAPTOPURINE; AGED; COLITIS; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROGNOSIS; PROPENSITY SCORE; RETROSPECTIVE STUDIES;

EID: 84878222995     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318289664c     Document Type: Article

References (13)

1. Lennard-Jones JE, Morson BC, Ritchie JK, et al. Cancer in colitis: assessment of individual risk by clinical and histological criteria. Gastroenterology. 1977;73:1280-1289.
2. Sugita A, Sachar DB, Bodian C, et al. Influence of anatomical extent and age of onset on colitis-cancer interval. Gut. 1991;32:167-169.
3. Korelitz BI. Crohn's colitis versus ulcerative colitis: should surveillance for dysplasia and cancer differ? Nat Clin Pract Gastroenterol Hepatol. 2009;6:144-145.
4. van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578.
5. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
6. Ullman T, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol. 2008;6:1225-1230.
7. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990;85:717-722.
8. Korelitz BI, Adler DJ, Mendelsohn RA, et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol. 1993;88:1198-1205.
9. George J, Present D, Pou R. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol. 1996;91:1711-1714.
10. Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol. 1999;94:3248-3253.
11. Actis GC, Pellicano R, David E, et al. Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical practice based forecast. Inflam Allergy Drug Targets. 2010;9:6-9.
12. Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol. 2005;3:1015-1021.
13. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.